Literature DB >> 23614333

Low hemorrhage-related mortality in trauma patients in a Level I trauma center employing transfusion packages and early thromboelastography-directed hemostatic resuscitation with plasma and platelets.

Pär I Johansson1, Anne Marie Sørensen, Claus F Larsen, Nis A Windeløv, Jakob Stensballe, Anders Perner, Lars S Rasmussen, Sisse R Ostrowski.   

Abstract

BACKGROUND: Hemorrhage accounts for most preventable trauma deaths, but still the optimal strategy for hemostatic resuscitation remains debated. STUDY DESIGN AND METHODS: This was a prospective study of adult trauma patients admitted to a Level I trauma center. Demography, Injury Severity Score (ISS), transfusion therapy, and mortality were registered. Hemostatic resuscitation was based on a massive transfusion protocol encompassing transfusion packages and thromboelastography (TEG)-guided therapy.
RESULTS: A total of 182 patients were included (75% males, median age 43 years, ISS of 17, 92% with blunt trauma). Overall 28-day mortality was 12% with causes of death being exsanguinations (14%), traumatic brain injury (72%, two-thirds expiring within 24 hr), and other (14%). One-fourth, 16 and 15% of the patients, received red blood cells (RBCs), plasma, or platelets (PLTs) within 2 hours from admission and 68, 71, and 75%, respectively, of patients transfused within 24 hours received the respective blood products within the first 2 hours. In patients transfused within 24 hours, the median number of blood products at 2 hours was 5 units of RBCs, 5 units of plasma, and 2 units of PLT concentrates. Nonsurvivors had lower clot strength by kaolin-activated TEG and TEG functional fibrinogen and lower kaolin-tissue factor-activated TEG α-angle and lysis after 30 minutes compared to survivors. None of the TEG variables were independent predictors of massive transfusion or mortality.
CONCLUSION: Three-fourths of the patients transfused with plasma or PLTs within 24 hours received these in the first 2 hours. Hemorrhage caused 14% of the deaths. We introduced transfusion packages and early TEG-directed hemostatic resuscitation at our hospital 10 years ago and this may have contributed to reducing hemorrhagic trauma deaths.
© 2013 American Association of Blood Banks.

Entities:  

Mesh:

Year:  2013        PMID: 23614333     DOI: 10.1111/trf.12214

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  30 in total

1.  Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial.

Authors:  John B Holcomb; Barbara C Tilley; Sarah Baraniuk; Erin E Fox; Charles E Wade; Jeanette M Podbielski; Deborah J del Junco; Karen J Brasel; Eileen M Bulger; Rachael A Callcut; Mitchell Jay Cohen; Bryan A Cotton; Timothy C Fabian; Kenji Inaba; Jeffrey D Kerby; Peter Muskat; Terence O'Keeffe; Sandro Rizoli; Bryce R H Robinson; Thomas M Scalea; Martin A Schreiber; Deborah M Stein; Jordan A Weinberg; Jeannie L Callum; John R Hess; Nena Matijevic; Christopher N Miller; Jean-Francois Pittet; David B Hoyt; Gail D Pearson; Brian Leroux; Gerald van Belle
Journal:  JAMA       Date:  2015-02-03       Impact factor: 56.272

2.  Hemostatic resuscitation is neither hemostatic nor resuscitative in trauma hemorrhage-But did they in fact test the effect of hemostatic resuscitation?

Authors:  Jakob Stensballe; John B Holcomb
Journal:  J Trauma Acute Care Surg       Date:  2015-06       Impact factor: 3.313

3.  The "Death Diamond": Rapid thrombelastography identifies lethal hyperfibrinolysis.

Authors:  Michael P Chapman; Ernest E Moore; Hunter B Moore; Eduardo Gonzalez; Alexander P Morton; James Chandler; Courtney D Fleming; Arsen Ghasabyan; Christopher C Silliman; Anirban Banerjee; Angela Sauaia
Journal:  J Trauma Acute Care Surg       Date:  2015-12       Impact factor: 3.313

4.  In vitro combinations of red blood cell, plasma and platelet components evaluated by thromboelastography.

Authors:  Anna Agren; Gustaf Edgren; Malin Kardell; Anders Ostlund; Agneta Taune Wikman
Journal:  Blood Transfus       Date:  2014-06-05       Impact factor: 3.443

Review 5.  Massive haemorrhage in liver transplantation: Consequences, prediction and management.

Authors:  Stuart Cleland; Carlos Corredor; Jia Jia Ye; Coimbatore Srinivas; Stuart A McCluskey
Journal:  World J Transplant       Date:  2016-06-24

6.  Multicenter observational prehospital resuscitation on helicopter study.

Authors:  John B Holcomb; Michael D Swartz; Stacia M DeSantis; Thomas J Greene; Erin E Fox; Deborah M Stein; Eileen M Bulger; Jeffrey D Kerby; Michael Goodman; Martin A Schreiber; Martin D Zielinski; Terence O'Keeffe; Kenji Inaba; Jeffrey S Tomasek; Jeanette M Podbielski; Savitri N Appana; Misung Yi; Charles E Wade
Journal:  J Trauma Acute Care Surg       Date:  2017-07       Impact factor: 3.313

7.  Rapid thrombelastography thresholds for goal-directed resuscitation of patients at risk for massive transfusion.

Authors:  Peter M Einersen; Ernest E Moore; Michael P Chapman; Hunter B Moore; Eduardo Gonzalez; Christopher C Silliman; Anirban Banerjee; Angela Sauaia
Journal:  J Trauma Acute Care Surg       Date:  2017-01       Impact factor: 3.313

8.  Rapid TEG efficiently guides hemostatic resuscitation in trauma patients.

Authors:  Julia R Coleman; Ernest E Moore; Michael P Chapman; Anirban Banerjee; Christopher C Silliman; Arsen Ghasabyan; James Chandler; Jason M Samuels; Angela Sauaia
Journal:  Surgery       Date:  2018-06-12       Impact factor: 3.982

9.  Recommendations on RBC Transfusion in Critically Ill Children With Nonlife-Threatening Bleeding or Hemorrhagic Shock From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative.

Authors:  Oliver Karam; Robert T Russell; Paul Stricker; Adam M Vogel; Scot T Bateman; Stacey L Valentine; Philip C Spinella
Journal:  Pediatr Crit Care Med       Date:  2018-09       Impact factor: 3.624

Review 10.  New Advances in the Care of the Hemorrhaging Patient.

Authors:  Tessa N Woods; Keela R Scott; Jacob A Quick
Journal:  Mo Med       Date:  2018 Sep-Oct
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.